Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 5

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 5
---
 to the People’s Republic of China. All references
to “Hong Kong” or “H.K.” in this prospectus refer to Hong Kong Special Administrative Region of the People’s
Republic of China. All references to the “United States,” “U.S.” or “US” refer to the United States
of America.

Unless otherwise noted in
this prospectus, disclosure herein including disclosure incorporated by reference herein pertains to Aptorum Group Limited, a Cayman Islands
exempted company with limited liability.

<div align='center'>i

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>

This prospectus, including
the sections titled “Prospectus Summary,” “Risk Factors,” “Our Business,” and “Operating and
Financial Review and Prospects” as well as information we incorporated herein by reference, contains forward-looking statements that
are based on our management’s belief and assumptions and on information currently available to our management. Although we believe
that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future
financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels
of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus and the documents incorporated
herein by reference include, but are not limited to, statements about:

| ● | the initiation, timing, progress and results of our preclinical and clinical trials, and our research and development programs; |

| ● | our ability to advance our drug candidates into, and successfully complete, clinical trials; |

| ● | our ability to identify and develop new drug and device candidates; |

| ● | our reliance on the success of our drug candidates currently undergoing preclinical development; in particular, our Lead Project candidates; |

| ● | the timing or likelihood of regulatory filings and approvals; |

| ● | the commercialization of our drug and device candidates, if approved; |

| ● | our ability to develop sales and marketing capabilities; |

| ● | the pricing and reimbursement of our drug candidates, if approved; |

| ● | the implementation of our business model, strategic plans for our business and technology; |

| ● | the scope of protection we are able to establish and maintain for IP rights covering our drug and device candidates and technology; |

| ● | our ability to operate our business without infringing the IP